U0126, an inhibitor of mitogen-activated protein kinase kinase (MEK) 1/2-mediated phosphorylation of ERK1/2 [40,41], was used to treat liver cancer cell lines in combination with oncoVV or oncoVV-TTL. Here, MAPK3 is linked to liver cancer.